Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
16 May 2021
16 May 2021
Historique:
entrez:
25
5
2021
pubmed:
26
5
2021
medline:
26
5
2021
Statut:
epublish
Résumé
SARS-CoV-2 mutations may diminish vaccine-induced protective immune responses, and the durability of such responses has not been previously reported. Here, we present a comprehensive assessment of the impact of variants B.1.1.7, B.1.351, P.1, B.1.429, and B.1.526 on binding, neutralizing, and ACE2-blocking antibodies elicited by the vaccine mRNA-1273 over seven months. Cross-reactive neutralizing responses were rare after a single dose of mRNA-1273. At the peak of response to the second dose, all subjects had robust responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of mRNA-1273. Across all assays, B.1.351 had the greatest impact on antibody recognition, and B.1.1.7 the least. These data complement ongoing studies of clinical protection to inform the potential need for additional boost vaccinations. Most mRNA-1273 vaccinated individuals maintained binding and functional antibodies against SARS-CoV-2 variants for 6 months.
Identifiants
pubmed: 34031659
doi: 10.1101/2021.05.13.444010
pmc: PMC8142657
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI148684
Pays : United States
Commentaires et corrections
Type : UpdateIn
Références
PLoS Biol. 2021 Apr 29;19(4):e3001237
pubmed: 33914735
N Engl J Med. 2021 Jun 24;384(25):2453-2454
pubmed: 33826815
N Engl J Med. 2021 Jul 8;385(2):187-189
pubmed: 33951357
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
N Engl J Med. 2021 Jun 3;384(22):2161-2163
pubmed: 33826816
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Cell Host Microbe. 2021 Apr 14;29(4):516-521.e3
pubmed: 33798491
Nature. 2021 Feb;590(7847):630-634
pubmed: 33276369
Cell Host Microbe. 2021 May 12;29(5):747-751.e4
pubmed: 33887205
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
mBio. 2021 Aug 31;12(4):e0138621
pubmed: 34311587
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
J Biol Chem. 2021 Jan-Jun;296:100536
pubmed: 33716040
Cell Rep. 2021 Apr 20;35(3):109017
pubmed: 33857422
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Cell. 2021 May 27;184(11):2939-2954.e9
pubmed: 33852911
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11382-8
pubmed: 8876144
Curr Protoc Immunol. 2020 Dec;131(1):e116
pubmed: 33215858
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862
pubmed: 30356267
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
J Virol. 2006 Oct;80(19):9896-8
pubmed: 16973594
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Science. 2021 Apr 30;:
pubmed: 33931567
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
N Engl J Med. 2021 Jun 17;384(24):2352-2354
pubmed: 33826819
Semin Immunol. 2018 Dec;40:83-94
pubmed: 30501873
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
N Engl J Med. 2020 Dec 17;383(25):2427-2438
pubmed: 32991794
Cell Res. 2021 Jun;31(6):720-722
pubmed: 33893398
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Nat Med. 2021 Apr;27(4):717-726
pubmed: 33664494
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
JAMA. 2021 May 11;325(18):1896-1898
pubmed: 33739374